跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

How Antibiotics Kill Bacteria and Why Resistance Develops

1Bacterial Targets: What Makes a Good Antibiotic Target2How Major Antibiotic Classes Kill Bacteria3Genetic Origins of Resistance: Mutation and Horizontal Gene Transfer4Biochemical Mechanisms of Resistance5Multidrug Resistance, Co-selection, and Clinical Consequences
Biochemical Mechanisms of Resistance

Destroying the Drug and Disguising the Target

1 / 3
Look at the two panels side by side. On the left, the drug is the thing that gets changed: a beta-lactamase opens the beta-lactam ring, or a modifying enzyme tags an aminoglycoside, and the altered drug can no longer bind. The target is untouched. On the right, the drug stays intact but the target is edited: PBP2a has low affinity for beta-lactams, methylated 23S rRNA rejects macrolides, and mutated gyrase no longer binds fluoroquinolones. Notice the shared requirement in both panels: the cell must keep doing the job the drug was blocking. A resistance mechanism that destroys the target's function would kill the cell anyway.
0:00 / 0:00

Two resistance strategies act at the point of contact between drug and target. Enzymatic inactivation uses a bacterial enzyme to chemically modify or cleave the antibiotic so it can no longer bind. Beta-lactamases hydrolyze the beta-lactam ring, the four-membered amide ring that gives penicillins and cephalosporins their reactive shape; once the ring opens, the drug cannot acylate its target penicillin-binding proteins (PBPs). Aminoglycoside-modifying enzymes instead attach acetyl, phosphoryl, or adenyl groups to the drug, and the bulky modification blocks binding to the 30S ribosomal subunit. In both cases the drug is consumed or altered before it reaches its target, so the target itself stays unchanged.

Target modification takes the opposite approach: the drug remains intact and active, but its binding site is altered. Methicillin-resistant Staphylococcus aureus (MRSA) carries the gene mecA, which encodes PBP2a, a PBP with low affinity for nearly all beta-lactams; the transpeptidation reaction that cross-links peptidoglycan still proceeds, but the drug can no longer inhibit it. Ribosomal methylation by Erm methyltransferases adds methyl groups to the 23S rRNA at the macrolide binding site, so macrolides, lincosamides, and streptogramin B can no longer block the exit tunnel. Mutations in the genes encoding DNA gyrase or topoisomerase IV change the fluoroquinolone binding pocket, so the drug cannot trap the enzyme-DNA complex. The unifying logic is that the essential function survives while the drug's grip is lost.

上一页1 / 3下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion